- Home
- ACAD vs LIF Comparison
ACAD vs LIF Comparison
Compare ACAD & LIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- LIF
- Stock Information
- Founded
- ACAD 1993
- LIF 2008
- Country
- ACAD United States
- LIF United States
- Employees
- ACAD N/A
- LIF N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- LIF
- Sector
- ACAD Health Care
- LIF
- Exchange
- ACAD Nasdaq
- LIF Nasdaq
- Market Cap
- ACAD 2.8B
- LIF 3.1B
- IPO Year
- ACAD 2004
- LIF N/A
- Fundamental
- Price
- ACAD $16.61
- LIF $38.39
- Analyst Decision
- ACAD Buy
- LIF Strong Buy
- Analyst Count
- ACAD 17
- LIF 7
- Target Price
- ACAD $24.00
- LIF $48.71
- AVG Volume (30 Days)
- ACAD 1.5M
- LIF 888.3K
- Earning Date
- ACAD 05-07-2025
- LIF 05-13-2025
- Dividend Yield
- ACAD N/A
- LIF N/A
- EPS Growth
- ACAD N/A
- LIF N/A
- EPS
- ACAD 1.36
- LIF N/A
- Revenue
- ACAD $957,797,000.00
- LIF $371,484,000.00
- Revenue This Year
- ACAD $13.07
- LIF $27.21
- Revenue Next Year
- ACAD $9.97
- LIF $22.20
- P/E Ratio
- ACAD $12.28
- LIF N/A
- Revenue Growth
- ACAD 31.85
- LIF 21.99
- 52 Week Low
- ACAD $14.15
- LIF $26.00
- 52 Week High
- ACAD $20.68
- LIF $52.77
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- LIF N/A
- Support Level
- ACAD $16.86
- LIF N/A
- Resistance Level
- ACAD $17.31
- LIF N/A
- Average True Range (ATR)
- ACAD 0.51
- LIF 0.00
- MACD
- ACAD -0.00
- LIF 0.00
- Stochastic Oscillator
- ACAD 23.24
- LIF 0.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About LIF Life360 Inc. Common Stock
Life360 is the world's largest family-focused social network, with over 50 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.